Table 2.
Results of assessed biomarkers in CKD patients and control group.
| Biomarkers | CKD patients before treatment | CKD patients after treatment | Control group |
|---|---|---|---|
| (n = 25) (Me; 25–75%) | (n = 25) (Me; 25–75%) | (n = 20) (Me; 25–75%) | |
| IL-1β (pg/mL) | 2.78 (2.00–3.36)∗ | 2.69 (2.48–3.15)∗ | 1.25 (0.89–1.65) |
| TNF-RI (pg/mL) | 4644 (4156–5677)∗ | 4979 (4236–6667)∗ | 1151 (930–1332) |
| TNF-RII (pg/mL) | 8010 (7298–8689)∗ | 9180 (8845–9908)∗° | 2351 (1900–2600) |
| sFasL (pg/mL) | 85.9 (68.0–109.9)∗ | 94.3 (75.6–103.8)∗ | 47.0 (30.5–80.0) |
| sFas (pg/mL) | 3272 (2734–3799)∗ | 3206 (2826–3715)∗ | 465.0 (368.0–645.0) |
| sE-selectin (ng/mL) | 28.3 (24.2–33.6)∗ | 33.5 (26.0–36.2)∗ | 15.5 (11.7–22.9) |
| sICAM-1 (ng/mL) | 402.0 (336.0–504.0)∗ | 466.0 (355.0–518.0)∗ | 242.0 (234.0–272.0) |
| TIMP-1 (ng/mL) | 203.0 (186.5–258.5)∗ | 212.0 (178.0–228.0)∗ | 110.0 (91.0–131.0) |
| sVCAM-1 (ng/mL) | 2380 (1326–2790)∗ | 2600 (1720–4129)∗° | 840.0 (760.0–1252.0) |
| MMP-9 (ng/mL) | 1062 (665–1455)∗ | 586.0 (450.0–764.0)∗° | 280.0 (217.0–292.0) |
| TGF-β1 (pg/mL) | 21.4 (19.0–30.1)∗ | 21.2 (16.5–29.3)∗ | 11.6 (9.7–15.5) |
∗ p < 0.05 versus control group; °p < 0.05 versus CKD patients before treatment.
CKD = chronic kidney disease, (Me; 25–75%) = median and interquartile range, IL-1β = interleukin 1β, TNF-RI = soluble tumor necrosis factor receptor I, TNF-RII = soluble tumor necrosis factor receptor II, sFasL = soluble Fas ligand, sFas = soluble Fas, sICAM-1 = soluble intercellular adhesion molecule-1, TIMP-1 = tissue inhibitor of metalloproteinase-1, sVCAM-1 = soluble human vascular cell adhesion molecule-1, MMP-9 = metalloproteinase-9, and TGF-β1 = transforming growth factor-beta 1.